WHWK WHITEHAWK THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, WHITEHAWK THERAPEUTICS INC reported revenue of $0, net income of −$16.6M and diluted EPS of −$0.20; over the last four quarters revenue was $0 and net income −$79.8M; for the fiscal year ended December 2025 revenue was $7.15M, down 72.5% on the year before.

WHWK annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $7.15M, gross profit n/a, operating income −$114M, net income −$20.6M (margin -288.3%), EPS −$0.33
• Fiscal year ended Dec 2024: revenue $26.0M, gross profit n/a, operating income −$67.5M, net income −$63.7M (margin -245.1%), EPS −$2.36
• Fiscal year ended Dec 2023: revenue $24.4M, gross profit n/a, operating income −$71.9M, net income −$65.8M (margin -270.0%), EPS −$2.44
• Fiscal year ended Dec 2022: revenue $15.2M, gross profit n/a, operating income −$62.7M, net income −$60.5M (margin -397.7%), EPS −$2.69
• Fiscal year ended Dec 2021: revenue $14.0M, gross profit n/a, operating income −$111M, net income −$110M (margin -786.4%), EPS −$12.41

WHWK quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0, net income −$16.6M, EPS −$0.20
• Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$22.2M, EPS −$0.32
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0 (down 100.0% year over year), net income −$23.3M, EPS −$1.14
• Quarter ended Sep 30, 2025: revenue $0 (down 100.0% year over year), net income −$17.7M, EPS −$0.26
• Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$52.6M, EPS −$0.76
• Quarter ended Mar 31, 2025: revenue $7.15M (up 33.5% year over year), net income $73.0M, EPS $1.83
• Quarter ended Dec 31, 2024 (from the annual report): revenue $7.24M (up 14.4% year over year), net income −$18.3M, EPS −$0.68
• Quarter ended Sep 30, 2024: revenue $7.21M (up 21.0% year over year), net income −$12.5M, EPS −$0.46
• Quarter ended Jun 30, 2024: revenue $6.18M (down 0.4% year over year), net income −$14.6M, EPS −$0.54
• Quarter ended Mar 31, 2024: revenue $5.35M (down 8.8% year over year), net income −$18.3M, EPS −$0.68
• Quarter ended Dec 31, 2023 (from the annual report): revenue $6.33M (up 21.0% year over year), net income −$16.3M, EPS −$0.60
• Quarter ended Sep 30, 2023: revenue $5.96M (up 40.4% year over year), net income −$16.3M, EPS −$0.60
• Quarter ended Jun 30, 2023: revenue $6.20M (up 80.4% year over year), net income −$18.0M, EPS −$0.67
• Quarter ended Mar 31, 2023: revenue $5.87M (up 154.3% year over year), net income −$15.2M, EPS −$0.57
• Quarter ended Dec 31, 2022 (from the annual report): revenue $5.23M (down 62.3% year over year), net income −$13.9M, EPS −$0.48
• Quarter ended Sep 30, 2022: revenue $4.25M, net income −$14.5M, EPS −$0.68
• Quarter ended Jun 30, 2022: revenue $3.44M, net income −$18.3M, EPS −$0.87
• Quarter ended Mar 31, 2022: revenue $2.31M (up 1822.5% year over year), net income −$13.9M, EPS −$0.66
• Quarter ended Dec 31, 2021 (from the annual report): revenue $13.9M, net income −$16.0M, EPS −$0.49
• Quarter ended Sep 30, 2021: revenue $0, net income −$87.1M, EPS −$9.17

WHWK cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$97.4M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$59.6M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$59.7M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$49.6M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$22.4M, share buybacks n/a

WHWK balance sheet

• Jun 30, 2026: cash $85.2M, total assets $194M, total liabilities $11.1M, shareholders' equity $183M
• Mar 31, 2026: cash $34.8M, total assets $127M, total liabilities $11.1M, shareholders' equity $116M
• Dec 31, 2025: cash $37.6M, total assets $151M, total liabilities $14.5M, shareholders' equity $136M
• Sep 30, 2025: cash $37.9M, total assets $167M, total liabilities $9.85M, shareholders' equity $157M
• Jun 30, 2025: cash $145M, total assets $181M, total liabilities $8.76M, shareholders' equity $172M
• Mar 31, 2025: cash $228M, total assets $234M, total liabilities $12.3M, shareholders' equity $222M
• Dec 31, 2024: cash $28.7M, total assets $70.3M, total liabilities $17.8M, shareholders' equity $52.5M
• Sep 30, 2024: cash $30.5M, total assets $85.7M, total liabilities $16.8M, shareholders' equity $68.9M

What is WHWK's revenue?

WHITEHAWK THERAPEUTICS INC reported $0 of revenue over its last four quarters, through June 30, 2026.

Is WHWK profitable?

No. WHITEHAWK THERAPEUTICS INC lost $79.8M over the last four quarters.

What is WHWK's EPS?

Diluted earnings per share over the last four quarters were −$1.92; −$0.20 in the latest quarter.

WHWK ownership and insider trades · All stocks